Nivolumab-refractory patients with advanced non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.01.015
Abstract: INTRODUCTION Immune checkpoint inhibitors (ICIs) have revolutionised cancer care especially in lung cancer. New response patterns have been described under ICIs such as pseudo-progression or hyper-progressive disease (HPD). The definition of HPD is yet to… read more here.
Keywords: advanced non; nivolumab refractory; refractory patients; lung cancer ... See more keywords
Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough.
Sign Up to like & getrecommendations! Published in 2022 at "Clinics in colon and rectal surgery"
DOI: 10.1055/s-0041-1740036
Abstract: Despite significant improvements in the management of ulcerative colitis (UC) in parallel with the evolution of therapeutic targets and novel biologics and small molecules, a subset of medically refractory patients still requires colectomy. Recent population-based… read more here.
Keywords: therapy chronic; refractory; refractory patients; ulcerative colitis ... See more keywords
Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of haematology"
DOI: 10.1111/bjh.18053
Abstract: Phosphatidylinositol 3 kinase (PI3K) inhibitors such as idelalisib have been associated with potentially severe autoimmune toxicity. In the present study, we demonstrate that relapsed refractory patients with chronic lymphocytic leukaemia treated with idelalisib rituximab on… read more here.
Keywords: refractory patients; relapsed refractory; cell; chronic lymphocytic ... See more keywords